 |
The Journal of Neuroscience, May 19, 2004, 24(20):4894-4902; doi:10.1523/JNEUROSCI.0861-04.2004
Previous Article
Neurobiology of Disease
A Seed for Alzheimer Amyloid in the Brain
Hideki Hayashi,1
Nobuyuki Kimura,2
Haruyasu Yamaguchi,3
Kazuhiro Hasegawa,4
Tatsuki Yokoseki,5
Masao Shibata,5
Naoki Yamamoto,1
Makoto Michikawa,1
Yasuhiro Yoshikawa,2
Keiji Terao,6
Katsumi Matsuzaki,7
Cynthia A. Lemere,8
Dennis J. Selkoe,8
Hironobu Naiki,4 and
Katsuhiko Yanagisawa1
1Department of Dementia Research, National Institute for Longevity Sciences, Obu 474-8522, Japan, 2Department of Biomedical Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan, 3Gunma University School of Health Sciences, Maebashi 371-8514, Japan, 4Division of Molecular Pathology, Department of Pathological Sciences, Faculty of Medical Sciences, University of Fukui, Matsuoka 910-1193, Japan, 5Department of Pharmaceutical Development, Ina Institute, Medical and Biological Laboratories Company Ltd., Terasawaoka, Ina 396-0002, Japan, 6Tsukuba Primate Center for Medical Sciences, National Institute for Infectious Diseases, Hachimandai, Tsukuba 305-0843, Japan, 7Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan, and 8Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115
A fundamental question about the early pathogenesis of Alzheimer's disease (AD) concerns how toxic aggregates of amyloid protein (A ) are formed from its nontoxic soluble form. We hypothesized previously that GM1 ganglioside-bound A (GA ) is involved in the process. We now examined this possibility using a novel monoclonal antibody raised against GA purified from an AD brain. Here, we report that GA has a conformation distinct from that of soluble A and initiates A aggregation by acting as a seed. Furthermore, GA generation in the brain was validated by both immunohistochemical and immunoprecipitation studies. These results imply a mechanism underlying the onset of AD and suggest that an endogenous seed can be a target of therapeutic strategy.
Key words: Alzheimer's disease; amyloid; amyloid protein; seed; ganglioside; raft
Received Dec 26, 2003;
revised April 14, 2004;
accepted April 15, 2004.
This article has been cited by other articles:

|
 |

|
 |
 
T. Ookoshi, K. Hasegawa, Y. Ohhashi, H. Kimura, N. Takahashi, H. Yoshida, R. Miyazaki, Y. Goto, and H. Naiki
Lysophospholipids induce the nucleation and extension of {beta}2-microglobulin-related amyloid fibrils at a neutral pH
Nephrol. Dial. Transplant.,
October 1, 2008;
23(10):
3247 - 3255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ariga, M. P. McDonald, and R. K. Yu
Thematic Review Series: Sphingolipids. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review
J. Lipid Res.,
June 1, 2008;
49(6):
1157 - 1175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Hatzifilippou, E. Koutsouraki, T. Banaki, M. Traka, V. G. Costa, and S. J. Baloyannis
Antibodies Against GM1 in Demented Patients
American Journal of Alzheimer's Disease and Other Dementias,
June 1, 2008;
23(3):
274 - 279.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Williamson, A. Usardi, D. P. Hanger, and B. H. Anderton
Membrane-bound {beta}-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism
FASEB J,
May 1, 2008;
22(5):
1552 - 1559.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yanagisawa and R. K Yu
The expression and functions of glycoconjugates in neural stem cells
Glycobiology,
July 1, 2007;
17(7):
57R - 74R.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. V. J. Murray, L. Liu, H. Komatsu, K. Uryu, G. Xiao, J. A. Lawson, and P. H. Axelsen
Membrane-mediated Amyloidogenesis and the Promotion of Oxidative Lipid Damage by Amyloid beta Proteins
J. Biol. Chem.,
March 30, 2007;
282(13):
9335 - 9345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Yamamoto, E. Matsubara, S. Maeda, H. Minagawa, A. Takashima, W. Maruyama, M. Michikawa, and K. Yanagisawa
A Ganglioside-induced Toxic Soluble Abeta Assembly: ITS ENHANCED FORMATION FROM AbetaBEARING THE ARCTIC MUTATION
J. Biol. Chem.,
January 26, 2007;
282(4):
2646 - 2655.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Isaacs, D. B. Senn, M. Yuan, J. P. Shine, and B. A. Yankner
Acceleration of Amyloid beta-Peptide Aggregation by Physiological Concentrations of Calcium
J. Biol. Chem.,
September 22, 2006;
281(38):
27916 - 27923.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Rajendran, M. Honsho, T. R. Zahn, P. Keller, K. D. Geiger, P. Verkade, and K. Simons
Alzheimer's disease beta-amyloid peptides are released in association with exosomes
PNAS,
July 25, 2006;
103(30):
11172 - 11177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kumar-Singh, D. Pirici, E. McGowan, S. Serneels, C. Ceuterick, J. Hardy, K. Duff, D. Dickson, and C. Van Broeckhoven
Dense-Core Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer's Disease Are Centered on Vessel Walls
Am. J. Pathol.,
August 1, 2005;
167(2):
527 - 543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Christopeit, P. Hortschansky, V. Schroeckh, K. Guhrs, G. Zandomeneghi, and M. Fandrich
Mutagenic analysis of the nucleation propensity of oxidized Alzheimer's {beta}-amyloid peptide
Protein Sci.,
August 1, 2005;
14(8):
2125 - 2131.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Y. Tamboli, K. Prager, E. Barth, M. Heneka, K. Sandhoff, and J. Walter
Inhibition of Glycosphingolipid Biosynthesis Reduces Secretion of the {beta}-Amyloid Precursor Protein and Amyloid {beta}-Peptide
J. Biol. Chem.,
July 29, 2005;
280(30):
28110 - 28117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Yanagisawa
GM1 Ganglioside and the Seeding of Amyloid in Alzheimer's Disease: Endogenous Seed for Alzheimer Amyloid
Neuroscientist,
June 1, 2005;
11(3):
250 - 260.
[Abstract]
[PDF]
|
 |
|
|